1. Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: a potent tool for identification and characterization of topoisomerase II-targeting antitumour agents

   • Benoît van Hille
   • Bridget T. Hill

   ORIGINAL ARTICLE Pages: 345 - 356

2. Mechanism and pharmacological specificity of dUTPase-mediated protection from DNA damage and cytotoxicity in human tumor cells

   • Leslie A. Parsels
   • Joshua D. Parsels
   • Jonathan Maybaum

   ORIGINAL ARTICLE Pages: 357 - 362

3. Pharmacokinetic analysis of high-dose toremifene in combination with doxorubicin

   • Gregory T. Wurz
   • Lin Soc
   • Michael W. DeGregorio

   ORIGINAL ARTICLE Pages: 363 - 366

4. Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone

   • Seiji Naito
   • Shuji Kotoh
   • The Kyushu University Urological Oncology Group

   ORIGINAL ARTICLE Pages: 367 - 372

5. Drug resistance to 5-aza-2′-deoxycytidine, 2′,2′-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells

   • Nicoletta Eliopoulos
   • Denis Cournoyer
   • Richard L. Momparler

   ORIGINAL ARTICLE Pages: 373 - 378

6. Pharmacokinetics and tissue distribution of the imidazoacridinone C1311 in tumour-bearing mice

   • Christopher R. Calabrese
   • Mike C. Bibby
   • Paul M. Loadman

   ORIGINAL ARTICLE Pages: 379 - 385

7. The influence of relative body weight on toxicity of combination chemotherapy with cisplatin and etoposide

   • Toshimichi Miya
   • Tomoyuki Goya
   • Yasutsuna Sasaki

   ORIGINAL ARTICLE Pages: 386 - 390

8. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity

   • Sally Mullany
   • Phyllis A. Svingen
   • Charles Erlichman

   ORIGINAL ARTICLE Pages: 391 - 399

9. Determination of the cytoprotective agent WR-2721 (Amifostine, Ethyol®) and its metabolites in human blood using monobromobimane fluorescent labeling and high-performance liquid chromatography

   • Abdul-Kader Souid
   • Gerald L. Newton
   • Mark L. Bernstein

   ORIGINAL ARTICLE Pages: 400 - 406

10. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker

    • Charles D. Conover
    • Richard B. Greenwald
    • Kwok L. Shum

    ORIGINAL ARTICLE Pages: 407 - 414

11. Phase II trial of titanocene dichloride in advanced renal-cell carcinoma

    • Gerd Lümmen
    • Herbert Sperling
    • Herbert Rübben

    CLINICAL TRIAL REPORT Pages: 415 - 417

12. Serum protein binding of lerisetron, a novel specific 5HT3 antagonist, in patients with cancer

    • Rosario Calvo
    • Rosa Ma Jiménez
    • Aurelio Orjales

    SHORT COMMUNICATION Pages: 418 - 422

13. Influence of piperacillin on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate

    • Tawfeeg A. Najjar
    • Hisham S. Abou-Auda
    • Naushad M. Ghilzai

    SHORT COMMUNICATION Pages: 423 - 428

14. Growth-inhibitory effects of the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivo

    • Simon P. Langdon
    • Genevieve J. Rabiasz
    • John F. Smyth

    SHORT COMMUNICATION Pages: 429 - 432